Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarkers of Tumor Angiogenesis and Response to Sunitinib Maleate in Renal Cell Carcinoma

NCT00747305 is registered in ClinicalTrials.gov with Harry Drabkin as lead sponsor.

NCT NCT00747305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00747305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarkers of Tumor Angiogenesis and Response to Sunitinib Maleate in Renal Cell Carcinoma
Lead sponsor
Harry Drabkin
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2008
Completion date
July 31, 2014
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer